Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study
We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors. We included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2024-09, Vol.116 (9), p.1495-1507 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1507 |
|---|---|
| container_issue | 9 |
| container_start_page | 1495 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 116 |
| creator | Mandelblatt, Jeanne Dage, Jeffrey L Zhou, Xingtao Small, Brent J Ahles, Tim A Ahn, Jaeil Artese, Ashley Bethea, Traci N Breen, Elizabeth C Carroll, Judith E Cohen, Harvey J Extermann, Martine Graham, Deena Claudine, Isaacs Jim, Heather S L McDonald, Brenna C Nakamura, Zev M Patel, Sunita K Rebeck, G William Rentscher, Kelly E Root, James C Russ, Kristen A Tometich, Danielle B Turner, R Scott Van Dyk, Kathleen Zhai, Wanting Huang, Li-Wen Saykin, Andrew J |
| description | We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors.
We included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (presystemic therapy) and annually for up to 60 months. Cognition was measured using tests of attention, processing speed, and executive function and learning and memory; perceived cognition was measured by the Functional Assessment of Cancer Therapy-Cognitive Function v3 Perceived Cognitive Impairments. Baseline plasma neurofilament light, glial fibrillary acidic protein, β-amyloid 42 and 40 and phosphorylated tau 181 were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD biomarkers, time, group (survivor vs control participant), and their 2- and 3-way interactions, controlling for age, race, Wide Range 4 Achievement Test Word Reading score, comorbidity, and body mass index; 2-sided P values of .05 were considered statistically significant.
There were no group differences in baseline AD-related biomarkers except survivors had higher baseline neurofilament light levels than control participants (P = .013). Survivors had lower adjusted longitudinal attention, processing speed, and executive function than control participants starting from baseline and continuing over time (P ≤ .002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except control participants had lower attention, processing speed, and executive function scores with higher glial fibrillary acidic protein levels (P = .008).
The results do not support a relationship between baseline AD-related biomarkers and cancer-related cognitive decline. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers, and examine other mechanisms and factors affecting cognition presystemic therapy. |
| doi_str_mv | 10.1093/jnci/djae113 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060372965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060372965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c221t-f4a46d8878520f78841ae92336ae62011393b0b4514694646cc4c5caa251ed843</originalsourceid><addsrcrecordid>eNo9UMtOwzAQtBCIlsKNM_KRA6F-xUm4oYqXVIlLOUeOvWnc5lFst6h8PemD7mVX2pnRzCB0S8kjJRkfL1ptx2ahgFJ-hoZUSBIxSuJzNCSEJVGaJmKArrxfkH4yJi7RgKdJmsokHqLwXP9WYBtw2FgPykPkoFYBDC5s1yi3BOexag3WqtXgTl_dzVsb7AawAV3bFp5wqADPKtsubTvfU6Z2szt_bKjwZE_HPqzN9hpdlKr2cHPcI_T1-jKbvEfTz7ePyfM00ozREJVCCWl6_2nMSNk7FlRBxjiXCiQjfd6MF6QQcZ85E1JIrYWOtVIspmBSwUfo_qC7ct33GnzIG-s11LVqoVv7nBNJeMIyGffQhwNUu857B2W-craPv80pyXc957ue82PPPfzuqLwuGjAn8H-x_A84Q3rs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3060372965</pqid></control><display><type>article</type><title>Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Mandelblatt, Jeanne ; Dage, Jeffrey L ; Zhou, Xingtao ; Small, Brent J ; Ahles, Tim A ; Ahn, Jaeil ; Artese, Ashley ; Bethea, Traci N ; Breen, Elizabeth C ; Carroll, Judith E ; Cohen, Harvey J ; Extermann, Martine ; Graham, Deena ; Claudine, Isaacs ; Jim, Heather S L ; McDonald, Brenna C ; Nakamura, Zev M ; Patel, Sunita K ; Rebeck, G William ; Rentscher, Kelly E ; Root, James C ; Russ, Kristen A ; Tometich, Danielle B ; Turner, R Scott ; Van Dyk, Kathleen ; Zhai, Wanting ; Huang, Li-Wen ; Saykin, Andrew J</creator><creatorcontrib>Mandelblatt, Jeanne ; Dage, Jeffrey L ; Zhou, Xingtao ; Small, Brent J ; Ahles, Tim A ; Ahn, Jaeil ; Artese, Ashley ; Bethea, Traci N ; Breen, Elizabeth C ; Carroll, Judith E ; Cohen, Harvey J ; Extermann, Martine ; Graham, Deena ; Claudine, Isaacs ; Jim, Heather S L ; McDonald, Brenna C ; Nakamura, Zev M ; Patel, Sunita K ; Rebeck, G William ; Rentscher, Kelly E ; Root, James C ; Russ, Kristen A ; Tometich, Danielle B ; Turner, R Scott ; Van Dyk, Kathleen ; Zhai, Wanting ; Huang, Li-Wen ; Saykin, Andrew J</creatorcontrib><description>We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors.
We included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (presystemic therapy) and annually for up to 60 months. Cognition was measured using tests of attention, processing speed, and executive function and learning and memory; perceived cognition was measured by the Functional Assessment of Cancer Therapy-Cognitive Function v3 Perceived Cognitive Impairments. Baseline plasma neurofilament light, glial fibrillary acidic protein, β-amyloid 42 and 40 and phosphorylated tau 181 were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD biomarkers, time, group (survivor vs control participant), and their 2- and 3-way interactions, controlling for age, race, Wide Range 4 Achievement Test Word Reading score, comorbidity, and body mass index; 2-sided P values of .05 were considered statistically significant.
There were no group differences in baseline AD-related biomarkers except survivors had higher baseline neurofilament light levels than control participants (P = .013). Survivors had lower adjusted longitudinal attention, processing speed, and executive function than control participants starting from baseline and continuing over time (P ≤ .002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except control participants had lower attention, processing speed, and executive function scores with higher glial fibrillary acidic protein levels (P = .008).
The results do not support a relationship between baseline AD-related biomarkers and cancer-related cognitive decline. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers, and examine other mechanisms and factors affecting cognition presystemic therapy.</description><identifier>ISSN: 0027-8874</identifier><identifier>ISSN: 1460-2105</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djae113</identifier><identifier>PMID: 38788675</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - blood ; Alzheimer Disease - psychology ; Amyloid beta-Peptides - blood ; Biomarkers - blood ; Breast Neoplasms - blood ; Breast Neoplasms - complications ; Breast Neoplasms - psychology ; Cancer Survivors - psychology ; Case-Control Studies ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - diagnosis ; Cognitive Dysfunction - etiology ; Female ; Glial Fibrillary Acidic Protein - blood ; Humans ; Middle Aged ; Neurofilament Proteins - blood ; Neuropsychological Tests ; tau Proteins - blood</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2024-09, Vol.116 (9), p.1495-1507</ispartof><rights>The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c221t-f4a46d8878520f78841ae92336ae62011393b0b4514694646cc4c5caa251ed843</citedby><cites>FETCH-LOGICAL-c221t-f4a46d8878520f78841ae92336ae62011393b0b4514694646cc4c5caa251ed843</cites><orcidid>0000-0003-4381-1199 ; 0000-0002-2490-005X ; 0000-0002-5164-125X ; 0000-0001-7332-6165 ; 0000-0001-7998-4759 ; 0000-0003-1500-930X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38788675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mandelblatt, Jeanne</creatorcontrib><creatorcontrib>Dage, Jeffrey L</creatorcontrib><creatorcontrib>Zhou, Xingtao</creatorcontrib><creatorcontrib>Small, Brent J</creatorcontrib><creatorcontrib>Ahles, Tim A</creatorcontrib><creatorcontrib>Ahn, Jaeil</creatorcontrib><creatorcontrib>Artese, Ashley</creatorcontrib><creatorcontrib>Bethea, Traci N</creatorcontrib><creatorcontrib>Breen, Elizabeth C</creatorcontrib><creatorcontrib>Carroll, Judith E</creatorcontrib><creatorcontrib>Cohen, Harvey J</creatorcontrib><creatorcontrib>Extermann, Martine</creatorcontrib><creatorcontrib>Graham, Deena</creatorcontrib><creatorcontrib>Claudine, Isaacs</creatorcontrib><creatorcontrib>Jim, Heather S L</creatorcontrib><creatorcontrib>McDonald, Brenna C</creatorcontrib><creatorcontrib>Nakamura, Zev M</creatorcontrib><creatorcontrib>Patel, Sunita K</creatorcontrib><creatorcontrib>Rebeck, G William</creatorcontrib><creatorcontrib>Rentscher, Kelly E</creatorcontrib><creatorcontrib>Root, James C</creatorcontrib><creatorcontrib>Russ, Kristen A</creatorcontrib><creatorcontrib>Tometich, Danielle B</creatorcontrib><creatorcontrib>Turner, R Scott</creatorcontrib><creatorcontrib>Van Dyk, Kathleen</creatorcontrib><creatorcontrib>Zhai, Wanting</creatorcontrib><creatorcontrib>Huang, Li-Wen</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><title>Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors.
We included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (presystemic therapy) and annually for up to 60 months. Cognition was measured using tests of attention, processing speed, and executive function and learning and memory; perceived cognition was measured by the Functional Assessment of Cancer Therapy-Cognitive Function v3 Perceived Cognitive Impairments. Baseline plasma neurofilament light, glial fibrillary acidic protein, β-amyloid 42 and 40 and phosphorylated tau 181 were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD biomarkers, time, group (survivor vs control participant), and their 2- and 3-way interactions, controlling for age, race, Wide Range 4 Achievement Test Word Reading score, comorbidity, and body mass index; 2-sided P values of .05 were considered statistically significant.
There were no group differences in baseline AD-related biomarkers except survivors had higher baseline neurofilament light levels than control participants (P = .013). Survivors had lower adjusted longitudinal attention, processing speed, and executive function than control participants starting from baseline and continuing over time (P ≤ .002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except control participants had lower attention, processing speed, and executive function scores with higher glial fibrillary acidic protein levels (P = .008).
The results do not support a relationship between baseline AD-related biomarkers and cancer-related cognitive decline. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers, and examine other mechanisms and factors affecting cognition presystemic therapy.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - psychology</subject><subject>Amyloid beta-Peptides - blood</subject><subject>Biomarkers - blood</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - psychology</subject><subject>Cancer Survivors - psychology</subject><subject>Case-Control Studies</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Cognitive Dysfunction - etiology</subject><subject>Female</subject><subject>Glial Fibrillary Acidic Protein - blood</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neurofilament Proteins - blood</subject><subject>Neuropsychological Tests</subject><subject>tau Proteins - blood</subject><issn>0027-8874</issn><issn>1460-2105</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UMtOwzAQtBCIlsKNM_KRA6F-xUm4oYqXVIlLOUeOvWnc5lFst6h8PemD7mVX2pnRzCB0S8kjJRkfL1ptx2ahgFJ-hoZUSBIxSuJzNCSEJVGaJmKArrxfkH4yJi7RgKdJmsokHqLwXP9WYBtw2FgPykPkoFYBDC5s1yi3BOexag3WqtXgTl_dzVsb7AawAV3bFp5wqADPKtsubTvfU6Z2szt_bKjwZE_HPqzN9hpdlKr2cHPcI_T1-jKbvEfTz7ePyfM00ozREJVCCWl6_2nMSNk7FlRBxjiXCiQjfd6MF6QQcZ85E1JIrYWOtVIspmBSwUfo_qC7ct33GnzIG-s11LVqoVv7nBNJeMIyGffQhwNUu857B2W-craPv80pyXc957ue82PPPfzuqLwuGjAn8H-x_A84Q3rs</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Mandelblatt, Jeanne</creator><creator>Dage, Jeffrey L</creator><creator>Zhou, Xingtao</creator><creator>Small, Brent J</creator><creator>Ahles, Tim A</creator><creator>Ahn, Jaeil</creator><creator>Artese, Ashley</creator><creator>Bethea, Traci N</creator><creator>Breen, Elizabeth C</creator><creator>Carroll, Judith E</creator><creator>Cohen, Harvey J</creator><creator>Extermann, Martine</creator><creator>Graham, Deena</creator><creator>Claudine, Isaacs</creator><creator>Jim, Heather S L</creator><creator>McDonald, Brenna C</creator><creator>Nakamura, Zev M</creator><creator>Patel, Sunita K</creator><creator>Rebeck, G William</creator><creator>Rentscher, Kelly E</creator><creator>Root, James C</creator><creator>Russ, Kristen A</creator><creator>Tometich, Danielle B</creator><creator>Turner, R Scott</creator><creator>Van Dyk, Kathleen</creator><creator>Zhai, Wanting</creator><creator>Huang, Li-Wen</creator><creator>Saykin, Andrew J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4381-1199</orcidid><orcidid>https://orcid.org/0000-0002-2490-005X</orcidid><orcidid>https://orcid.org/0000-0002-5164-125X</orcidid><orcidid>https://orcid.org/0000-0001-7332-6165</orcidid><orcidid>https://orcid.org/0000-0001-7998-4759</orcidid><orcidid>https://orcid.org/0000-0003-1500-930X</orcidid></search><sort><creationdate>20240901</creationdate><title>Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study</title><author>Mandelblatt, Jeanne ; Dage, Jeffrey L ; Zhou, Xingtao ; Small, Brent J ; Ahles, Tim A ; Ahn, Jaeil ; Artese, Ashley ; Bethea, Traci N ; Breen, Elizabeth C ; Carroll, Judith E ; Cohen, Harvey J ; Extermann, Martine ; Graham, Deena ; Claudine, Isaacs ; Jim, Heather S L ; McDonald, Brenna C ; Nakamura, Zev M ; Patel, Sunita K ; Rebeck, G William ; Rentscher, Kelly E ; Root, James C ; Russ, Kristen A ; Tometich, Danielle B ; Turner, R Scott ; Van Dyk, Kathleen ; Zhai, Wanting ; Huang, Li-Wen ; Saykin, Andrew J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c221t-f4a46d8878520f78841ae92336ae62011393b0b4514694646cc4c5caa251ed843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - psychology</topic><topic>Amyloid beta-Peptides - blood</topic><topic>Biomarkers - blood</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - psychology</topic><topic>Cancer Survivors - psychology</topic><topic>Case-Control Studies</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Cognitive Dysfunction - etiology</topic><topic>Female</topic><topic>Glial Fibrillary Acidic Protein - blood</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neurofilament Proteins - blood</topic><topic>Neuropsychological Tests</topic><topic>tau Proteins - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mandelblatt, Jeanne</creatorcontrib><creatorcontrib>Dage, Jeffrey L</creatorcontrib><creatorcontrib>Zhou, Xingtao</creatorcontrib><creatorcontrib>Small, Brent J</creatorcontrib><creatorcontrib>Ahles, Tim A</creatorcontrib><creatorcontrib>Ahn, Jaeil</creatorcontrib><creatorcontrib>Artese, Ashley</creatorcontrib><creatorcontrib>Bethea, Traci N</creatorcontrib><creatorcontrib>Breen, Elizabeth C</creatorcontrib><creatorcontrib>Carroll, Judith E</creatorcontrib><creatorcontrib>Cohen, Harvey J</creatorcontrib><creatorcontrib>Extermann, Martine</creatorcontrib><creatorcontrib>Graham, Deena</creatorcontrib><creatorcontrib>Claudine, Isaacs</creatorcontrib><creatorcontrib>Jim, Heather S L</creatorcontrib><creatorcontrib>McDonald, Brenna C</creatorcontrib><creatorcontrib>Nakamura, Zev M</creatorcontrib><creatorcontrib>Patel, Sunita K</creatorcontrib><creatorcontrib>Rebeck, G William</creatorcontrib><creatorcontrib>Rentscher, Kelly E</creatorcontrib><creatorcontrib>Root, James C</creatorcontrib><creatorcontrib>Russ, Kristen A</creatorcontrib><creatorcontrib>Tometich, Danielle B</creatorcontrib><creatorcontrib>Turner, R Scott</creatorcontrib><creatorcontrib>Van Dyk, Kathleen</creatorcontrib><creatorcontrib>Zhai, Wanting</creatorcontrib><creatorcontrib>Huang, Li-Wen</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mandelblatt, Jeanne</au><au>Dage, Jeffrey L</au><au>Zhou, Xingtao</au><au>Small, Brent J</au><au>Ahles, Tim A</au><au>Ahn, Jaeil</au><au>Artese, Ashley</au><au>Bethea, Traci N</au><au>Breen, Elizabeth C</au><au>Carroll, Judith E</au><au>Cohen, Harvey J</au><au>Extermann, Martine</au><au>Graham, Deena</au><au>Claudine, Isaacs</au><au>Jim, Heather S L</au><au>McDonald, Brenna C</au><au>Nakamura, Zev M</au><au>Patel, Sunita K</au><au>Rebeck, G William</au><au>Rentscher, Kelly E</au><au>Root, James C</au><au>Russ, Kristen A</au><au>Tometich, Danielle B</au><au>Turner, R Scott</au><au>Van Dyk, Kathleen</au><au>Zhai, Wanting</au><au>Huang, Li-Wen</au><au>Saykin, Andrew J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>116</volume><issue>9</issue><spage>1495</spage><epage>1507</epage><pages>1495-1507</pages><issn>0027-8874</issn><issn>1460-2105</issn><eissn>1460-2105</eissn><abstract>We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors.
We included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (presystemic therapy) and annually for up to 60 months. Cognition was measured using tests of attention, processing speed, and executive function and learning and memory; perceived cognition was measured by the Functional Assessment of Cancer Therapy-Cognitive Function v3 Perceived Cognitive Impairments. Baseline plasma neurofilament light, glial fibrillary acidic protein, β-amyloid 42 and 40 and phosphorylated tau 181 were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD biomarkers, time, group (survivor vs control participant), and their 2- and 3-way interactions, controlling for age, race, Wide Range 4 Achievement Test Word Reading score, comorbidity, and body mass index; 2-sided P values of .05 were considered statistically significant.
There were no group differences in baseline AD-related biomarkers except survivors had higher baseline neurofilament light levels than control participants (P = .013). Survivors had lower adjusted longitudinal attention, processing speed, and executive function than control participants starting from baseline and continuing over time (P ≤ .002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except control participants had lower attention, processing speed, and executive function scores with higher glial fibrillary acidic protein levels (P = .008).
The results do not support a relationship between baseline AD-related biomarkers and cancer-related cognitive decline. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers, and examine other mechanisms and factors affecting cognition presystemic therapy.</abstract><cop>United States</cop><pmid>38788675</pmid><doi>10.1093/jnci/djae113</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-4381-1199</orcidid><orcidid>https://orcid.org/0000-0002-2490-005X</orcidid><orcidid>https://orcid.org/0000-0002-5164-125X</orcidid><orcidid>https://orcid.org/0000-0001-7332-6165</orcidid><orcidid>https://orcid.org/0000-0001-7998-4759</orcidid><orcidid>https://orcid.org/0000-0003-1500-930X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 2024-09, Vol.116 (9), p.1495-1507 |
| issn | 0027-8874 1460-2105 1460-2105 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3060372965 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Aged Aged, 80 and over Alzheimer Disease - blood Alzheimer Disease - psychology Amyloid beta-Peptides - blood Biomarkers - blood Breast Neoplasms - blood Breast Neoplasms - complications Breast Neoplasms - psychology Cancer Survivors - psychology Case-Control Studies Cognitive Dysfunction - blood Cognitive Dysfunction - diagnosis Cognitive Dysfunction - etiology Female Glial Fibrillary Acidic Protein - blood Humans Middle Aged Neurofilament Proteins - blood Neuropsychological Tests tau Proteins - blood |
| title | Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A03%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alzheimer%20disease-related%20biomarkers%20and%20cancer-related%20cognitive%20decline:%20the%20Thinking%20and%20Living%20with%20Cancer%20study&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Mandelblatt,%20Jeanne&rft.date=2024-09-01&rft.volume=116&rft.issue=9&rft.spage=1495&rft.epage=1507&rft.pages=1495-1507&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/djae113&rft_dat=%3Cproquest_cross%3E3060372965%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3060372965&rft_id=info:pmid/38788675&rfr_iscdi=true |